Crystal D C Kamilaris1, Fabio R Faucz1, Victoria C Andriessen1, Naris Nilubol2, Chyi-Chia Richard Lee3, Mark A Ahlman4, Fady Hannah-Shmouni1, Constantine A Stratakis1. 1. Section on Endocrinology and Genetics (SEGEN), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA. 2. Endocrine Surgery Section, Surgical Oncology Program, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. 3. Laboratory of Pathology, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. 4. Radiology and Imaging Sciences, Clinical Center, National Institutes of Health (NIH), Bethesda, MD, USA.
Abstract
CONTEXT: Primary pigmented nodular adrenocortical disease (PPNAD) is a rare cause of ACTH-independent Cushing syndrome (CS) associated mostly with Carney complex (CNC), a rare autosomal dominant multiple neoplasia syndrome. More than two-thirds of familial cases and approximately one-third of sporadic cases of CNC harbor germline inactivating PRKAR1A defects. Increasingly sensitive technologies for the detection of genetic defects such as next-generation sequencing (NGS) have further highlighted the importance of mosaicism in human disease. CASE DESCRIPTION: A 33-year-old woman was diagnosed with ACTH-independent CS with abdominal computed tomography showing bilateral micronodular adrenal hyperplasia with a left adrenal adenoma. She underwent left adrenalectomy with pathology demonstrating PPNAD with a 1.5-cm pigmented adenoma. DNA analysis by Sanger sequencing revealed 2 different PRKAR1A variants in the adenoma that were absent from DNA extracted from blood and saliva: c.682C > T and c.974-2A > G. "Deep" NGS revealed that 0.31% of DNA copies extracted from blood and saliva did in fact carry the c.682C > T variant, suggesting low-level mosaicism for this defect. CONCLUSIONS: We present a case of PPNAD due to low-level mosaicism for a PRKAR1A defect which led to the formation of an adenoma due to a second, adrenal-specific, somatic PRKAR1A mutation. The identification of mosaicism for PRKAR1A, depending on the number and distribution of cells affected has implications for genetic counseling and tumor surveillance. This is the first recorded case of a patient with PRKAR1A mosaicism, PPNAD, and an adenoma forming due to complete inactivation of PRKAR1A in adrenal tissue from a second, somatic-only, PRKAR1A coding sequence mutation. Published by Oxford University Press on behalf of the Endocrine Society 2021.
CONTEXT: Primary pigmented nodular adrenocortical disease (PPNAD) is a rare cause of ACTH-independent Cushing syndrome (CS) associated mostly with Carney complex (CNC), a rare autosomal dominant multiple neoplasia syndrome. More than two-thirds of familial cases and approximately one-third of sporadic cases of CNC harbor germline inactivating PRKAR1A defects. Increasingly sensitive technologies for the detection of genetic defects such as next-generation sequencing (NGS) have further highlighted the importance of mosaicism in human disease. CASE DESCRIPTION: A 33-year-old woman was diagnosed with ACTH-independent CS with abdominal computed tomography showing bilateral micronodular adrenal hyperplasia with a left adrenal adenoma. She underwent left adrenalectomy with pathology demonstrating PPNAD with a 1.5-cm pigmented adenoma. DNA analysis by Sanger sequencing revealed 2 different PRKAR1A variants in the adenoma that were absent from DNA extracted from blood and saliva: c.682C > T and c.974-2A > G. "Deep" NGS revealed that 0.31% of DNA copies extracted from blood and saliva did in fact carry the c.682C > T variant, suggesting low-level mosaicism for this defect. CONCLUSIONS: We present a case of PPNAD due to low-level mosaicism for a PRKAR1A defect which led to the formation of an adenoma due to a second, adrenal-specific, somatic PRKAR1A mutation. The identification of mosaicism for PRKAR1A, depending on the number and distribution of cells affected has implications for genetic counseling and tumor surveillance. This is the first recorded case of a patient with PRKAR1A mosaicism, PPNAD, and an adenoma forming due to complete inactivation of PRKAR1A in adrenal tissue from a second, somatic-only, PRKAR1A coding sequence mutation. Published by Oxford University Press on behalf of the Endocrine Society 2021.
Authors: M Cignarelli; G Picca; M Campo; M Margaglione; A Marino; F Logoluso; F Giorgino Journal: J Endocrinol Invest Date: 2005-01 Impact factor: 4.256
Authors: Paraskevi Salpea; Anelia Horvath; Edra London; Fabio R Faucz; Annalisa Vetro; Isaac Levy; Evgenia Gourgari; Andrew Dauber; Ingrid A Holm; Patrick J Morrison; Margaret F Keil; Charalampos Lyssikatos; Eric D Smith; Marc A Sanidad; JoAnn C Kelly; Zunyan Dai; Philip Mowrey; Antonella Forlino; Orsetta Zuffardi; Constantine A Stratakis Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: T Iwata; T Tamanaha; R Koezuka; M Tochiya; H Makino; I Kishimoto; N Mizusawa; S Ono; N Inoshita; S Yamada; A Shimatsu; K Yoshimoto Journal: Eur J Endocrinol Date: 2014-10-21 Impact factor: 6.664
Authors: Kathleen M Lowe; William F Young; Charalampos Lyssikatos; Constantine A Stratakis; J Aidan Carney Journal: Am J Surg Pathol Date: 2017-02 Impact factor: 6.394
Authors: A H Prowse; A R Webster; F M Richards; S Richard; S Olschwang; F Resche; N A Affara; E R Maher Journal: Am J Hum Genet Date: 1997-04 Impact factor: 11.025
Authors: Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm Journal: Genet Med Date: 2015-03-05 Impact factor: 8.822